3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
2
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Breast Neoplasms
45
Carcinoma, Non-Small-Cell Lung
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Sarcoma, Synovial
1
Rhabdomyosarcoma
1
Recurrence
1
Pleuropulmonary blastoma
1
Patient Preference
1
Pancreatic Neoplasms
1
Neurofibrosarcoma
1
Neuroblastoma
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Inflammatory Breast Neoplasms
1
HER2 Positive Breast Cancer
1
Genomic Instability
1
Cholangiocarcinoma
1
Breast Cancer Metastatic
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
Gemcitabine
79
Cisplatin
56
pembrolizumab
32
Paclitaxel
28
Carboplatin
24
Docetaxel
19
Radiotherapy
17
Mitomycin
16
Doxorubicin
15
atezolizumab
14
BCG Vaccine
14
Nivolumab
13
Cystectomy
13
Filgrastim
11
vinflunine
10
Methotrexate
10
Vinblastine
9
Fluorouracil
9
5-aminolevulinic acid hexyl ester
9
Sunitinib
7
Early Intervention, Educational
7
durvalumab
6
avelumab
6
Taxes
6
Methods
6
Cystoscopy
6
Albumin-Bound Paclitaxel
6
enfortumab vedotin
5
Trastuzumab
5
Surveys and Questionnaires
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Urinary Bladder Neoplasms
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT02999672
2019-08-28
KAMELEON
Hoffmann-La Roche
Phase 2
Completed
20 enrolled
14 charts